This is the authors' abstract. We don't add key points for this paper.
The emergence of drug-resistant pathogens necessitates the development of novel antimicrobial and antiviral agents. In this study, a series of 2,6-diaminobenzobisthiazole derivatives were synthesized and evaluated for their antimicrobial and antiviral activities. The antimicrobial screening revealed that compounds 4, 6, 10, and 20 exhibited potent activity against Gram-positive ( S. aureus ) and Gram-negative ( E. coli , P. aeruginosa ) bacteria, with minimum inhibitory concentrations (MICs) as low as 3.125 µg/mL, comparable to standard antibiotics such as chloramphenicol. Additionally, these compounds demonstrated significant antifungal effects against C . albicans , highlighting their broad-spectrum potential. Antiviral assessments against the H5N1 virus demonstrated that compounds 3 and 4 achieved 91% and 87% inhibition, respectively, at 0.25 µM concentration, suggesting promising antiviral efficacy. Molecular docking studies further validated the biological activity, revealing strong interactions between potent compounds and Pseudomonas aeruginosa DNA gyrase (PDB: 3TYE), supporting their potential mechanism of action. Overall, this study highlights the promising therapeutic potential of 2,6-diaminobenzobisthiazole derivatives as potent antimicrobial and antiviral agents, warranting further investigation for clinical applications.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Attar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: